These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

631 related items for PubMed ID: 17626072

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, Chou J, Chen CS, Xiao JJ, Parthun M, Chan KK, Eisenbeis CF, Ferketich AK, Grever MR, Chen CS, Caligiuri MA.
    J Natl Cancer Inst; 2004 Oct 06; 96(19):1447-57. PubMed ID: 15467034
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
    Bu R, Hussain AR, Al-Obaisi KA, Ahmed M, Uddin S, Al-Kuraya KS.
    Leuk Lymphoma; 2014 Feb 06; 55(2):415-24. PubMed ID: 23697845
    [Abstract] [Full Text] [Related]

  • 8. Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis.
    Kawada J, Zou P, Mazitschek R, Bradner JE, Cohen JI.
    J Biol Chem; 2009 Jun 19; 284(25):17102-17109. PubMed ID: 19386607
    [Abstract] [Full Text] [Related]

  • 9. Ascorbic acid kills Epstein-Barr virus positive Burkitt lymphoma cells and Epstein-Barr virus transformed B-cells in vitro, but not in vivo.
    Shatzer AN, Espey MG, Chavez M, Tu H, Levine M, Cohen JI.
    Leuk Lymphoma; 2013 May 19; 54(5):1069-78. PubMed ID: 23067008
    [Abstract] [Full Text] [Related]

  • 10. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
    Perez-Chacon G, de Los Rios C, Zapata JM.
    Pharmacol Res; 2014 Nov 19; 89():46-56. PubMed ID: 25180456
    [Abstract] [Full Text] [Related]

  • 11. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R, Tokuhira M, Ri M, Hashimoto Y, Iida S, Kizaki M.
    Cancer Sci; 2015 Apr 19; 106(4):438-46. PubMed ID: 25613668
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
    De Leo A, Arena G, Stecca C, Raciti M, Mattia E.
    Mol Cancer Res; 2011 Oct 19; 9(10):1346-55. PubMed ID: 21856773
    [Abstract] [Full Text] [Related]

  • 14. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
    Abdulkarim B, Sabri S, Zelenika D, Deutsch E, Frascogna V, Klijanienko J, Vainchenker W, Joab I, Bourhis J.
    Oncogene; 2003 Apr 17; 22(15):2260-71. PubMed ID: 12700662
    [Abstract] [Full Text] [Related]

  • 15. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE, Rundall BK, Keller MD, Jones DR.
    Ann Thorac Surg; 2004 Oct 17; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [Abstract] [Full Text] [Related]

  • 16. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
    Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P, Grant S.
    Br J Haematol; 2011 Apr 17; 153(2):222-35. PubMed ID: 21375523
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC.
    Clin Cancer Res; 2011 Aug 15; 17(16):5311-21. PubMed ID: 21724551
    [Abstract] [Full Text] [Related]

  • 18. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.
    Cancer Res; 2007 Jun 01; 67(11):5418-24. PubMed ID: 17545623
    [Abstract] [Full Text] [Related]

  • 19. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 20. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
    Tamatani T, Takamaru N, Hara K, Kinouchi M, Kuribayashi N, Ohe G, Uchida D, Fujisawa K, Nagai H, Miyamoto Y.
    Int J Oncol; 2013 Mar 01; 42(3):935-44. PubMed ID: 23340716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.